Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to down-stage large oestrogen receptor positive breast cancer

新辅助化疗/同步芳香酶抑制剂内分泌治疗对大雌激素受体阳性乳腺癌进行降期的随机 II 期试验

• 批准号: nhmrc : 1066479
• 负责人: A/Pr Andrew Redfern
• 金额: $ 153.53万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-phase-ii-breast-cancer/455238
• 关键词: Randomised; phase; II; trial; neoadjuvant

Women diagnosed with large oestrogen receptor positive breast cancer are often treated with chemotherapy before surgery to reduce the size of the cancer, while treatment to lower oestrogen levels is given after surgery. This trial is studying if combining chemotherapy with oestrogen lowering treatment before surgery will better shrink the cancer which can improve the surgery options.

被诊断患有大雌激素受体阳性乳腺癌的妇女通常在手术前接受化疗以减少癌症的大小，而手术后给予降低雌激素水平的治疗。这项试验正在研究手术前联合化疗和降低雌激素治疗是否能更好地缩小癌症，从而改善手术选择。